Report of Foreign Issuer (6-k)
April 12 2019 - 4:06PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES
AND EXCHANGE COMMISSION
W
ashington,
D.C.
20549
FORM 6-K
Report of Foreign Private Issuer
Pursuant to Rule 13a-16 or 15d-16
of the Securities Exchange Act of 1934
For the month of April 2019
Commission File Number: 001-37643
KITOV PHARMA
LTD.
(Translation of registrant’s name into
English)
One Azrieli Center, Round Tower,
132 Menachem Begin Road, Tel Aviv 6701101,
Israel
(Address of principal executive offices)
Indicate by check mark whether the registrant
files or will file annual reports under cover Form 20-F or Form 40-F.
Form 20-F ☒ Form
40-F ☐
Indicate by check mark if the registrant is
submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ____
Indicate by check mark if the registrant is
submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ____
FameWave Ltd. (“FameWave”),
which is being acquired by Kitov Pharma Ltd. (the “Company” or the “Registrant”) as previously announced,
subject to fulfillment of the closing conditions, announced the signing of a clinical collaboration with Bristol Myers Squibb
Company to evaluate the combination of CM-24, FameWave’s monoclonal antibody targeting the novel immune checkpoint carcinoembryonic
antigen-related cell adhesion molecule 1 (CEACAM1), with nivolumab (Opdivo®), a PD-1 inhibitor, in patients with non-small
cell lung cancer (NSCLC). FameWave and Bristol Myers Squibb will coordinate on the protocol design for the Phase 1/2 clinical
trial in a well-defined patient population with NSCLC. Under the terms of the agreement, FameWave will fund and sponsor the study
and Bristol Myers Squibb will supply nivolumab. On April 12, 2019, FameWave issued a press release announcing the clinical collaboration,
“
FameWave Announces Clinical Collaboration with Bristol Myers Squibb for the Planned Phase 1/2 Trial in Non-Small Cell
Lung Cancer to Evaluate Immuno-Oncology Candidate CM-24 in Combination with Nivolumab (Opdivo®)
,” which is attached
hereto as Exhibit 99.1.
On April 12, 2019, the Company
announced the execution of the clinical collaboration agreement between FameWave and Bristol Myers Squibb, a key milestone in the
acquisition of FameWave, and issued a press release “
Kitov Announces Key Milestone in FameWave Acquisition,”
which
is attached hereto as Exhibit 99.2.
Forward-Looking Statements and
the Company’s Safe Harbor Statement
Certain statements in this Report on Form
6-K are forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform
Act of 1995 and other applicable securities laws. Forward-looking statements can be identified by the use of forward-looking words
such as “believe”, “expect”, “intend”, “plan”, “may”, “should”,
“could”, “might”, “seek”, “target”, “will”, “project”,
“forecast”, “continue” or “anticipate” or their negatives or variations of these words or other
comparable words or by the fact that these statements do not relate strictly to historical matters. You should not place undue
reliance on these forward-looking statements, which are not guarantees of future performance. Forward-looking statements reflect
our current views, expectations, beliefs or intentions with respect to future events, and are subject to a number of assumptions,
involve known and unknown risks, many of which are beyond our control, as well as uncertainties and other factors that may cause
our actual results, performance or achievements to be significantly different from any future results, performance or achievements
expressed or implied by the forward-looking statements. Any forward-looking statement in this Report on Form 6-K speaks only as
of the date which it is made. We disclaim any intention or obligation to publicly update or revise any forward-looking statement,
or other information contained herein, whether as a result of new information, future events or otherwise, except as required by
applicable law. You are advised, however, to consult any additional disclosures we make in our reports to the SEC, which are available
on the SEC’s website, http://www.sec.gov
This Form 6-K, excluding Exhibits
99.1 and 99.2, is incorporated by reference into each of the Registrant’s Registration Statements on Form F-3 filed with
the Securities and Exchange Commission on December 12, 2016 (Registration file numbers 333-207117, 333-211477 and 333-215037),
the Registrant’s Registration Statement on Form S-8 filed with the Securities and Exchange Commission on May 20, 2016 (Registration
file number 333-211478), the Registrant’s Registration Statement on Form S-8 filed with the Securities and Exchange Commission
on June 6, 2017 (Registration file number 333-218538), the Registrant’s Registration Statement on Form F-3, as amended, originally
filed with the Securities and Exchange Commission on July 16, 2018 (Registration file number 333-226195), and the Registrant’s
Registration Statement on Form S-8 filed with the Securities and Exchange Commission on March 28, 2019 (Registration file number
333-230584).
SIGNATURES
Pursuant to the requirements of the Securities
Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly
authorized.
|
KITOV PHARMA LTD.
|
|
|
April 12, 2019
|
By:
|
/s/ Simcha Rock
|
|
|
Simcha Rock
|
|
|
CFO & Director
|
Kitov Pharma (NASDAQ:KTOV)
Historical Stock Chart
From Mar 2024 to Apr 2024
Kitov Pharma (NASDAQ:KTOV)
Historical Stock Chart
From Apr 2023 to Apr 2024